Neurology

Back to articles

Promising oral drugs in the pipeline for relapsing–remitting MS

KEY POINT

Results from three Phase III studies, one with oral cladribine and two with oral fingolimod (FTY720), showed that these novel therapies improved relapse rates and endpoints on magnetic resonance imaging (MRI) in patients with relapsing–remitting multiple sclerosis (MS).

SOURCES

Giovannoni G et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362:416–26.

Cohen JA et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.

Kappos L et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.